Bladder cancer can cause pain when it spreads to different areas of the body. From NSAIDs to nerve blocks, here are the ...

ByEllis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008, 26(30):4875-4882. doi: ...

On January 19, 2026, Hikma announced the U.S. launch of ENOBY (denosumab-qbde) and XTRENBO (denosumab-qbde)—denosumab biosimilars referencing Amgen’s PROLIA and XGEVA, respectively. As recited in the ...

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

Korean regulators have approved two denosumab biosimilars from HK inno.N, setting up a sharper fight in a market where Amgen’s Prolia (denosumab) and Xgeva (denosumab) have generated more than 180 ...

Researchers conducted a retrospective cohort study using data from the TriNetX US Collaborative Network to compare the risk for incident OA in adults with osteoporosis treated with denosumab vs ...

Dialysis patients have a high risk of osteoporosis, leading to increasedfracture and mortality rates. Denosumab is commonly used in thispopulation due to its lack of renal accumulation, but its ...

1Dana-Farber-Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts. *Corresponding Author: Katherine A. Janeway, Department of Pediatric Oncology, Dana-Farber-Boston Children’s ...

Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in oncology care while enhancing patient outcomes. The rising cost of oncology care ...

Credit: Celltrion. The FDA originally approved Stoboclo and Osenvelt as biosimilars in March 2025. The interchangeability designation allows Stoboclo and Osenvelt to be substituted at the pharmacy for ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...